FDA WARNING_LETTER - Leading Edge Health Inc. - May 01, 2026

On June 17, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Leading Edge Health Inc. following an evaluation of the company"s website conducted in May 2026. The agency identified significant violations of the Federal Food, Drug, and Cosmetic Act regarding the marketing of two specific products: "Erectin Stimulating Gel" and "VigRX Delay Wipes." The FDA determined that these items are classified as unapproved new drugs because they are intended to treat medical conditions or affect the structure and function of the body without prior agency approval. For instance, the company marketed the products for physical performance and therapeutic effects such as numbing and improved circulation. Because these products are not generally recognized as safe and effective for their advertised uses, their distribution in interstate commerce is illegal. The FDA has instructed Leading Edge Health Inc. to investigate the root causes of these violations and implement corrective measures. The company is required to submit a written response within 15 business days outlining the steps taken to address the issues and prevent future occurrences. Failure to comply with these requirements may result in further legal actions, including product seizures or injunctions.